Osaic Holdings
CLDX icon

Osaic Holdings’s Celldex Therapeutics CLDX Stock Holding History

Osaic Holdings’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$32.1K Sell
862
-90
-9% -$2.91K ﹤0.01% 5800
2026
Q1 		$30.2K Sell
952
-181
-16% -$4.93K ﹤0.01% 5574
2025
Q4 		$30.8K Buy
1,133
+385
+51% +$10.1K ﹤0.01% 5572
2025
Q3 		$18.9K Buy
748
+83
+12% +$1.92K ﹤0.01% 5965
2025
Q2 		$13.4K Buy
665
+408
+159% +$7.94K ﹤0.01% 5979
2025
Q1 		$4.66K Sell
257
-208
-45% -$4.65K ﹤0.01% 6223
2024
Q4 		$11.7K Sell
465
-26
-5% -$706 ﹤0.01% 5678
2024
Q3 		$16.7K Sell
491
-198
-29% -$7.54K ﹤0.01% 5487
2024
Q2 		$25.5K Sell
689
-71
-9% -$2.68K ﹤0.01% 5170
2024
Q1 		$31.9K Buy
760
+213
+39% +$8.75K ﹤0.01% 5057
2023
Q4 		$21.7K Sell
547
-146
-21% -$4.29K ﹤0.01% 5453
2023
Q3 		$19.1K Sell
693
-117
-14% -$3.67K ﹤0.01% 5588
2023
Q2 		$27.5K Sell
810
-98
-11% -$3.3K ﹤0.01% 5351
2023
Q1 		$32.7K Sell
908
-57
-6% -$2.46K ﹤0.01% 5260
2022
Q4 		$42K Sell
965
-69
-7% -$2.46K ﹤0.01% 5057
2022
Q3 		$29K Sell
1,034
-10
-1% -$307 ﹤0.01% 5313
2022
Q2 		$28K Buy
1,044
+66
+7% +$1.92K ﹤0.01% 5372
2022
Q1 		$32K Buy
978
+39
+4% +$1.25K ﹤0.01% 5397
2021
Q4 		$37K Buy
939
+27
+3% +$1.18K ﹤0.01% 5365
2021
Q3 		$49K Sell
912
-10
-1% -$469 ﹤0.01% 5120
2021
Q2 		$31K Hold
922
– – ﹤0.01% 5384
2021
Q1 		$18K Sell
922
-13
-1% -$299 ﹤0.01% 5546
2020
Q4 		$16K Sell
935
-399
-30% -$7.18K ﹤0.01% 5282
2020
Q3 		$20K Buy
1,334
+13
+1% +$152 ﹤0.01% 4900
2020
Q2 		$17K Buy
1,321
+367
+38% +$1.63K ﹤0.01% 4889
2020
Q1 		$1K Buy
+954
New +$2.16K ﹤0.01% 5808

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Osaic Holdings's CLDX Position: Q2 2026 in Review

Osaic Holdings reduced its Celldex Therapeutics (CLDX) stake by 9.5% in Q2 2026, selling an estimated $2.91K and leaving 862 shares worth $32.1K. The position accounts for ﹤0.01% of the portfolio, ranked #5800.

Osaic Holdings first reported a position in CLDX in Q1 2020 and has held it in 26 quarters since. The position peaked at $49K in Q3 2021. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • Osaic Holdings held 862 shares of Celldex Therapeutics worth $32.1K as of Q2 2026.
  • Osaic Holdings sold 90 Celldex Therapeutics shares in Q2 2026, an estimated $2.91K.
  • Celldex Therapeutics made up ﹤0.01% of Osaic Holdings's portfolio in Q2 2026, its #5800 holding.
  • Osaic Holdings first reported a position in Celldex Therapeutics in Q1 2020 and has held it in 26 quarters since.
  • Osaic Holdings's Celldex Therapeutics position peaked at $49K in Q3 2021.
  • 253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Osaic Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.